TD Cowen reissued a buy rating on NeoGenomics.
1 report, 1 independent
Updated Sep 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen reissued a buy rating on NeoGenomics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
NeoGenomics
cancer genetics diagnostic testing company based in Fort Myers, Florida, USA
Nothing else this week.
Related events
- TD Cowen provided research reports on Adaptive Biotechnologies on August 1, 2026.
- Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
- TD Cowen reaffirmed a buy rating on Tectonic Therapeutic (TECX) on October 13, 2026.
- TD Cowen upgraded the stock rating for Generac on October 6, 2026.